The paradigm of lung cancer: from therapy selection to resistance monitoring

Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation sequencing panels have proven to be powerful tools for multi-marker analysis and here, we describe the use of an all-in one lung panel to detect mutations in lung tumor samples. In addition, we have been able to identify specific mutations in liquid biopsies—such as CNVs and gene fusions—that are important drivers of resistance in NSCLC.

 

Learning Objectives